Glenmark launches generic version of nintedanib for the treatment of pulmonary fibrosis in India

October 14, 2020 0 By FM

Glenmark Pharmaceuticals has launched the generic version of nintedanib capsules under the brand name Nindanib for the treatment of pulmonary fibrosis in India.

The tablets will be available in two doses at 100 and 150 mg which is priced at Rs. 4500 and Rs. 5400 per month respectively. The drug is made available at 5 % of the cost as compared to the innovator brand in India providing patients with a far more cost-effective treatment option, announced the company.

Nintedanib is approved by the Indian drug regulator for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Since IPF is a progressive disease that worsens over time, starting treatment early and continuing treatment are important to slow disease progression. A lower monthly treatment cost, therefore, becomes crucial to ensure patients adhere to prescribed treatment in the long term.

Pulmonary fibrosis (PF) is a respiratory condition characterized by thickening and/or scarring of the lungs, making breathing difficult and reducing patient life spans. The average survival rate in patients with IPF is poor, with only 20 to 30 per cent of people surviving at least five years after diagnosis if left untreated. The most frequent cause of death is respiratory failure. IPF typically affects men over the age of 65 in India. Patients with IPF may also be at higher risk of developing severe respiratory conditions if affected by COVID-19.

So far Nintedanib has been studied extensively in various controlled clinical trials that have established its efficacy and safety. In a recently published INBUILD trial, nintedanib showed a significantly lower annual rate of decline in FVC (Forced Vital Capacity) – a measure of lung health – with various progressive fibrosing interstitial lung diseases.

Moreover, two clinical trials are being rolled out to study the efficacy and safety of nintedanib as a treatment of SARS-COV-2 induced pulmonary fibrosis in moderate to severe COVID-19 patients.